Gene Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRXM research report →
Price Chart
About the company
Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials.
- CEO
- Christopher J. Reinhard
- IPO
- 2000
- Employees
- 3
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CRXM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.49K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 12.69%
- ROIC
- 38.15%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,816+96.9%
- Op Income
- $-1,262,000
- Net Income
- $-518,000-159.8%
- EPS
- $-0.02-140.0%
- OCF Growth
- -726.0%
- FCF Growth
- -728.5%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 19.29
- RSI (14)
- 54
- Avg Volume
- 0
No earnings-call transcripts are available for CRXM yet.
- Free Float
- 93.8%
- Shares Outstanding
- 64.93M
- Float Shares
- 60.93M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 21 | Jemapete Christopher J | other | 0 |
| Mar 17, 21 | Jemapete Christopher J | buy | 200,000 |
| Mar 16, 21 | Jemapete Christopher J | buy | 300,000 |
| Feb 26, 21 | Jemapete Christopher J | other | 0 |
| Feb 26, 21 | Jemapete Christopher J | other | 0 |
| May 22, 20 | MULYE NIRMAL | other | 69,911,504 |
| May 22, 20 | MULYE NIRMAL | other | 150,442,478 |
| May 22, 20 | Grainer James L | other | 0 |
| May 22, 20 | Vyas Kaushik K. | other | 0 |
| May 22, 20 | Shebuski Ronald J. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRXM coverage
Recent articles, reports, and earnings notes.
No research on CRXM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRXM report →